Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 63, Issue 19, Pages 10816-10828Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c00149
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81860630, 81560577, 81360485]
- Natural Science Foundation of Jiangxi [20181BAB205087]
- Key Project of Jiangxi [20192ACB70012]
- Jiangxi University of Traditional Chinese Medicine [1050]
Ask authors/readers for more resources
Floxuridine (FUdR, 5-fluoro-2-deoxyuridine) was widely used in patients with tumor. But the poor activity and severe side effects have been observed in the clinic, which resulted from increased degradation cleavage of FUdR to 5-FU by thymidine phosphorylase and reduced transporter-mediated entry into cells. In this study, we have synthesized a series of L-aspartic acid beta-esters and L-glutamic acid gamma-esters of FUdR to improve the metabolic stability of FUdR and target FUdR to cancer cells via amino acid transporter ATB(0,+) which was exclusively up-regulated in some cancerous tissue. The uptake mechanism, stability, in vitro/in vivo antiproliferation action, pharmacokinetics, and tissue distribution were studied. The combined results showed the unusual 5'-beta-L-Asp-FUdR possessed a better tumor inhibition rate and a better metabolic stability than FUdR through a ATB(0,+)-mediated prodrug approach. The present study provided the first proof-of-concept of exploiting ATB(0,+) for tumor-selective delivery of nucleoside analogues in the form of prodrug.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available